Gilead Sciences, Inc.
333 Lakeside Drive
Tel: 800-GILEAD-5 or 650-574-3000
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
CEO: John F. Milligan, PhD
Chief Scientific Officer: Norbert W. Bischofberger, PhD
CFO: Robin L. Washington
COO: Kevin Young
Please click here for clinical trial information.
1311 articles with Gilead Sciences, Inc.
It’s no secret that China has become an ever-increasing important component for drug development. Not only is the country seen as a lucrative market for drugs, entities within the country are making heavy investments in the global biotech industry.
Ahead of next Monday’s U.S. Food and Drug Administration (FDA) committee review of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis, concerns over blood clots, may scuttle the drug’s chances.
4/13/2018Less than one week after licensing three non-alcoholic steatohepatitis (NASH) programs from Eli Lilly, startup company Terns Pharmaceuticals has strengthened its leadership team with the appointment of two scientific advisors.
Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress™ 2018
-- Combination Therapy Data Presented from First 12-Week Study -- -- Enrollment Complete for Phase 3 STELLAR Trials of ASK1 Inhibitor Selonsertib --
Investors in Ionis Pharmaceuticals are happy this morning after the company announced it struck another licensing deal with AstraZeneca that has the potential to yield up to $330 million.
When it comes to large-cap biotech companies, Gilead Sciences, Biogen and Celgene are always worth investment consideration, but are not without their risks.
If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.
The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three small molecule therapeutic NASH candidates from Eli Lilly.
Days after being tapped to helm the U.S. Centers for Disease Control and Prevention, Dr. Robert Redfield predicted the AIDs epidemic can be defeated within the next three to seven years and the challenges of the opioid crisis can also be brought “to its knees.”
The U.S. Food and Drug Administration (FDA) approved Mylan NV’s Symfi (efavirnenz, lamivudine and tenofovir disoproxil fumarate) for adult and pediatric HIV-1 patients.This marks the third HIV approval for the company.
The head of GlaxoSmithKline's pharmaceuticals division is pushing to cut its budget by 20 percent.
3/20/2018Gilead Sciences essentially created a cure for hepatitis C and may be well on its way to developing a cure for HIV-AIDS.
Here are six biotech companies that should benefit the most from research-and-development spending trends that are expected to stimulate biotech development.
On April 23, the FDA’s arthritis advisory committee will take another look at Eli Lilly's re-submission for their moderate-to-severe rheumatoid arthritis drug.
After serving nearly 30 years with the company Norbert Bischofberger is stepping down from his role as head of research and development and chief scientific officer of Gilead Sciences.
Gilead Sciences’ Norbert Bischofberger, PhD, to Step Down; John McHutchison, MD, Appointed Chief Scientific Officer and Andrew Cheng, MD, PhD, Appointed Chief Medical Officer
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Norbert Bischofberger, PhD, has decided to step down from his role as Executive Vice President, Research and Development and Chief Scientific Officer, effective at the end of April 2018.
The National Pharmaceutical Council, a health policy research organization based in Washington, DC, today welcomed four biopharmaceutical companies to its growing membership roster.
Gilead Sciences announced promising results from a preclinical trial conducted with Beth Israel Deaconess Medical Center as part of an HIV eradication strategy.
Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lamivudine
Gilead Sciences, Inc. announced detailed 48-week results from a Phase 3 study (Study 1844) evaluating the efficacy and safety of switching from a regimen containing abacavir, dolutegravir and lamivudine (600/50/300mg) (ABC/DTG/3TC) to Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg).
Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) From a Boosted Protease Inhibitor-Based Regimen or Boosted Elvitegravir-Containing Regimen
Women in Biktarvy Treatment Arm Maintained High Rates of Virologic Suppression With No Adverse-Event Discontinuations and No Treatment-Emergent Resistance Through 48 Weeks